ONCE Spark Therapeutics Inc.

98.34
+0.34  (+0%)
Previous Close 98
Open 98.16
Price To Book 8.38
Market Cap 3,777,560,283
Shares 38,413,263
Volume 50,484
Short Ratio
Av. Daily Volume 550,623

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated late 2018. Phase 1/2 further data due mid-2019.
SPK-8011
Hemophilia A
Phase 1/2 updated data released May 22, 2018 - 98% decrease in bleeding rate.
SPK-9001
Hemophilia B
Phase 1/2 ongoing.
SPK-7001 (SPK-CHM)
Choroideremia
PDUFA date January 12, 2018 under priority review. Advisory Committee Meeting October 12, 2017 voted 16-0 in favor of recommending approval. Approval announced December 19, 2017.
Luxturna (voretigene neparvovec)
Inherited retinal dystrophies
Phase 3 lead-in trial initiation announced July 16, 2018.
FIX Replacement therapy
Hemophilia B